Full metadata record
DC FieldValueLanguage
dc.creatorRodriguez, J. (José)-
dc.creatorConde, E. (Eulogio)-
dc.creatorGutierrez, A. (Antonio)-
dc.creatorLahuerta, J.J. (Juan José)-
dc.creatorArranz, R. (R.)-
dc.creatorSureda, A. (Anna)-
dc.creatorZuazu, J. (Javier)-
dc.creatorFernandez-de-Sevilla, A. (A.)-
dc.creatorBendandi, M. (Maurizio)-
dc.creatorSolano, C. (C.)-
dc.creatorLeon, A. (Angel)-
dc.creatorVarela, M.R. (María Rosario)-
dc.creatorCaballero, M.D. (M.D.)-
dc.creatorGrupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL-TAMO)-
dc.date.accessioned2011-11-30T12:38:15Z-
dc.date.available2011-11-30T12:38:15Z-
dc.date.issued2007-
dc.identifier.citationRodriguez J, Conde E, Gutierrez A, Lahuerta JJ, Arranz R, Sureda A, et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007 Aug;92(8):1067-1074.es_ES
dc.identifier.issn1592-8721-
dc.identifier.urihttp://hdl.handle.net/10171/20025-
dc.description.abstractBACKGROUND AND OBJECTIVES: Preliminary data on the use of autologous stem cell transplantation (ASCT) as a salvage therapy for peripheral T-cell lymphoma (PTCL) indicate that the results are similar to those obtained in aggressive B-cell lymphomas. The aim of our study was to analyze outcomes of a large series of patients with PTCL with a prolonged follow-up who received ASCT as salvage therapy. DESIGN AND METHODS: Between 1990 and 2004, 123 patients in this situation were registered in the GELTAMO database. The median age at transplantation was 43.5 years; in 91% of patients the disease was chemosensitive. RESULTS: Seventy-three percent of the patients achieved complete remission, 11% partial remission and the procedure failed in 16%. At a median follow-up of 61 months, the 5-year overall and progression-free survival rates were 45% and 34%, respectively. The presence of more than one factor of the adjusted International Prognostic Index (a-IPI) and a high beta2-microglobulin at transplantation were identified as adverse prognostic factors for both overall and progression-free survival and allowed the population to be stratified into three distinct risk groups. INTERPRETATION AND CONCLUSIONS: Our data show that approximately one third of patients with PTCL in the salvage setting may enjoy prolonged survival following ASCT, provided they are transplanted in a chemosensitive disease state. The a-IPI and beta2-microglobulin level predict the outcome after ASCT in relapsing/refractory PTCL.es_ES
dc.language.isoenges_ES
dc.publisherFerrata Storti Foundationes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectPeripheral T-cell lymphomaes_ES
dc.subjectInternational prognostic indexes_ES
dc.subjectβ-2-microglobulines_ES
dc.subjectAutologous stem cell transplantationes_ES
dc.titleThe adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphomaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://www.haematologica.org/content/92/8/1067.longes_ES

Files in This Item:
File: 
Haematologica 2007_92 .pdf
Description: 
Size: 
240,23 kB
Format: 
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.